EV
EVH.US Evolent Health Inc
- Market cap
- USD 554M
- P/E
- -
- P/B
- 1.45x
- ROE
- -28.1%
- Dividend yield
- 2.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EVH.US undervalued?
Graham numberThe Graham number of Evolent Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evolent Health Inc fundamental analysis
No fundamental analysis for Evolent Health Inc yet.
Evolent Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evolent Health Inc
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technolo…
Full company profileEvolent Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evolent Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 254M | 435M | 627M | 687M | 925M | 908M | 1.35B | 1.96B | 2.55B | 1.88B | 2.50B |
| Gross Profit | 99.0M | 166M | 299M | 174M | 228M | 250M | 317M | 460M | 367M | 284M | 308M |
| Operating Income | -237M | -72.8M | -47.5M | -309M | -263M | -42.4M | 3.64M | -71.2M | -40.5M | -4.44M | -18.0M |
| EBITDA | -220M | -40.4M | -4.15M | -255M | -241M | 55.7M | 43.7M | -24.8M | 80.1M | -361M | 56.6M |
| Net Income | -160M | -60.7M | -52.7M | -302M | -334M | -37.6M | -19.2M | -113M | -61.6M | -535M | -105M |
| EPS | -3.55 | -0.94 | -0.68 | -3.67 | -3.94 | -0.44 | -0.20 | -1.02 | -0.54 | -4.68 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 1.20B | 1.31B | 1.72B | 1.50B | 1.47B | 1.42B | 1.82B | 2.68B | 2.54B | 1.90B | 1.96B |
| Total Liabilities | 288M | 266M | 533M | 569M | 855M | 726M | 958M | 1.61B | 1.54B | 1.48B | 1.59B |
| Shareholders' Equity | 912M | 1.05B | 1.19B | 922M | 620M | 694M | 859M | 1.07B | 1.00B | 415M | 373M |
| Cash & Short-term Investments | 179M | 238M | 228M | 103M | 333M | 266M | 188M | 193M | 163M | 152M | 148M |
| Total Debt | 120M | 121M | 344M | 369M | 360M | 280M | 476M | 645M | 714M | 990M | 973M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.5M | -28.0M | -20.7M | -42.6M | -16.2M | 38.7M | -11.6M | 143M | 18.8M | 38.8M | 20.1M |
| Capital Expenditure | 15.5M | 27.8M | 39.6M | 35.5M | 29.5M | 25.0M | 38.4M | 28.7M | 24.9M | 34.1M | 35.8M |
| Free Cash Flow | -51.0M | -55.8M | -60.2M | -78.2M | -45.7M | 13.8M | -49.9M | 114M | -6.13M | 4.76M | -15.7M |
| Ratios | |||||||||||
| ROE | -17.5% | -5.8% | -4.4% | -32.7% | -53.9% | -5.4% | -2.2% | -10.6% | -6.2% | -128.7% | -28.1% |
| ROA | -13.3% | -4.6% | -3.1% | -20.2% | -22.7% | -2.6% | -1.1% | -4.2% | -2.4% | -28.1% | -5.3% |
| Net Profit Margin | -62.8% | -13.9% | -8.4% | -43.9% | -36.1% | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% | -4.2% |
| Debt to Equity | 0.13x | 0.12x | 0.29x | 0.40x | 0.58x | 0.40x | 0.55x | 0.60x | 0.71x | 2.38x | 2.61x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evolent Health Inc dividends
- Dividend yield
- 2.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 11.1M | 0.10 | - |
| 2024 | USD 20.1M | 0.18 | - |
| 2023 | USD 18.8M | 0.17 | - |
| 2022 | USD 14.9M | 0.16 | - |
| 2021 | USD 1.30M | 0.02 | - |
| 2020 | USD 20.0M | 0.24 | - |
| 2019 | USD 61.1M | 0.74 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Evolent Health Inc
- Insiders 3.73%
- Institutions 95.30%
- Public & others 0.97%
- Shares outstanding 113M
- Free float 94.3M
Top funds holding EVH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.38M | 2.99% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.83M | 2.51% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.51M | 1.33% | +3.70% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.41M | 1.25% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 1.32M | 1.16% | +5.19% | Aug 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 1.14M | 1.01% | 0.00% | Oct 2026 |
| Nuveen Quant Small/Mid Cap Eq R6 | 1.04M | 0.92% | +46.29% | Aug 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 1.02M | 0.90% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 840K | 0.74% | +46.34% | Aug 2026 |
| Janus Henderson Small/Md Cp Gr Alpha ETF | 830K | 0.73% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 688K | 0.61% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 657K | 0.58% | -0.08% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 548K | 0.48% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 455K | 0.40% | -20.92% | Sep 2026 |
| GuideStone Funds Small Cap Equity Instl | 435K | 0.38% | +1.97% | Oct 2026 |
| Vanguard Explorer Inv | 412K | 0.36% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 386K | 0.34% | -0.38% | Oct 2026 |
| DFA U.S. Small Cap Value I | 381K | 0.34% | +41.22% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 374K | 0.33% | 0.00% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 302K | 0.27% | -3.57% | Sep 2026 |
Top institutions holding EVH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 14.8M | 13.10% | +36.06% | Jun 2026 |
| Cadian Capital Management LP | 10.8M | 9.56% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 8.97M | 7.93% | -1.23% | Jun 2026 |
| UBS Group AG | 6.25M | 5.52% | -23.37% | Jun 2026 |
| Rubicon Founders LLC | 5.82M | 5.14% | 0.00% | Jun 2026 |
| Engaged Capital LLC | 5.56M | 4.92% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 5.11M | 4.52% | -6.01% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.79M | 4.23% | -1.63% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 3.41M | 3.02% | +334.80% | Jun 2026 |
| Nuveen, LLC | 3.13M | 2.77% | +1,081.29% | Jun 2026 |
| Geode Capital Management, LLC | 2.90M | 2.57% | +10.94% | Jun 2026 |
| Rock Springs Capital Management LP | 2.50M | 2.21% | -6.54% | Jun 2026 |
| State Street Corp | 2.46M | 2.18% | -7.03% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.13M | 1.88% | +9.34% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.75M | 1.54% | -21.94% | Jun 2026 |
| Rock Point Advisors, LLC | 1.72M | 1.52% | -3.74% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.60M | 1.42% | +162.52% | Jun 2026 |
| Kennedy Capital Management Inc | 1.57M | 1.39% | -1.87% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.35M | 1.19% | +44.79% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.28M | 1.13% | 0.00% | Jun 2026 |
Evolent Health Inc company profile
- Company name
- Evolent Health Inc
- Ticker
- EVH.US
- Exchange
- USA Stocks
- Listed since
- Jun 5, 2015
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 4,200
- Fiscal year end
- December
- Address
- 1812 N. Moore Street, Arlington, VA, United States, 22209
- Phone
- 571 389 6000
- Website
- evolent.com
About Evolent Health Inc
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Evolent Health Inc management
10- Mr. Seth Barrie BlackleyCo-Founder, CEO & Director · born 1979
- Mr. Dan McCarthyPresident · born 1985
- Mr. Jonathan David Weinberg J.D.Chief Legal Officer, General Counsel & Secretary · born 1968
- Mr. John Paul JohnsonChief Strategy Officer · born 1984
- Mr. Mario Marques RamosChief Financial Officer · born 1972
- Ms. Katie DiPerna CookChief Operating Officer
- Mr. Aammaad ShamsChief Accounting Officer · born 1984
- Mr. Robert CruzChief Technology Officer
- Ms. Jessica WhiteChief Information Officer
- Dr. John Tam M.D.Chief Growth Officer